<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854942</url>
  </required_header>
  <id_info>
    <org_study_id>10-002</org_study_id>
    <nct_id>NCT03854942</nct_id>
  </id_info>
  <brief_title>Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System</brief_title>
  <official_title>Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System: a [18F]-Fallypride- and [18F]-Fluoro-DOPA-PET Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      About 10% of the calculable loss of health and quality of life in industrial countries can be&#xD;
      attributed to excessive alcohol consumption. Behavioural pharmacological, genetic and&#xD;
      clinical studies on alcohol dependence suggest a multifactorial model for the development of&#xD;
      the disease, which ascribes an important role in the development of the disease to genetic&#xD;
      variance, educational style and continued substance use. Animal and human experimental&#xD;
      studies suggest that continued alcohol consumption leads to a pathological activation of the&#xD;
      mesolimbic reward system. In the presented study, the modification of the alcohol-mediated&#xD;
      activation of the mesolimbic reward system by the administration of the opiate antagonist&#xD;
      naltrexone will be investigated in a human in vivo model. The aim is to gain important&#xD;
      insights for the further development of pharmacological treatment options for alcohol&#xD;
      dependence. Further development of pharmacological treatment options for alcohol dependence&#xD;
      seems urgently necessary in order to slow down the high tendency to relapse and prolong the&#xD;
      short abstinence period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment rate could not be met in the study period, review group was dissolved before&#xD;
    regular end of study. Recruitment was therefore terminated.&#xD;
  </why_stopped>
  <start_date type="Actual">August 30, 2011</start_date>
  <completion_date type="Actual">December 13, 2017</completion_date>
  <primary_completion_date type="Actual">December 13, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacological effect of naltrexone on the dopamine synthesis rate of a healthy OPRM1 Asp40-bearing men under the influence of alcohol measured with [18F]-fluoro-DOPA PET.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dopamine D2 receptor availability in the structures of the ventral and dorsal striatum of a healthy µ-opioid receptor gen (OPRM1, Asp40 Allel)-bearing men under the influence of alcohol measured with [18F]-fallypride Positron Emission Tomography.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacological effect of ethanol on dopamine D2 receptor availability in healthy men measured with [18F]-fallypride Positron Emission Tomography.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacological effect of ethanol on the dopamine synthesis rate of the ventral and dorsal striatum in healthy men measured with [18F]-fluoro-DOPA PET.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacological effect of Naltrexone on dopamine D2 receptor availability in healthy men measured with [18F]-fallypride Positron Emission Tomography.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacological effect of Naltrexone on the dopamine synthesis rate of ventral and dorsal striatum in healthy men measured with [18F]-fluoro-DOPA PET.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Modulation of extrastriatal dopamine D2/D3 receptor availability measured with [18F]-fallypride in structures of the anterior cingulum using Positron Emission Tomography.</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Relationship between impulsive behaviour and functionality of the dopamine synthesis rate and dopamine D2 receptor availability</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluation of impulsive behaviour using BIS (Barratt Impulsiveness Scale) questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship between impulsive behaviour and functionality of the dopamine synthesis rate and dopamine D2 receptor availability</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluation of impulsive behaviour using Neo-FFI (NEO-Fünf-Faktoren-Inventar) questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship between impulsive behaviour and functionality of the dopamine synthesis rate and dopamine D2 receptor availability</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluation of impulsive behaviour using I7 (Impulsivitätsfragebogen (impulsivity questionnaire) nach Eysenck) questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Interaction between subjective alcohol effects and placebo/naltrexone effects</measure>
    <time_frame>28 days</time_frame>
    <description>Exploratively, the interaction between subjective alcohol effects and placebo/naltrexone effects will be investigated using VAS (visual analogue scale of alcoholic desire) questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Interaction between subjective alcohol effects and placebo/naltrexone effects</measure>
    <time_frame>28 days</time_frame>
    <description>Exploratively, the interaction between subjective alcohol effects and placebo/naltrexone effects will be investigated using OCDS (Obsessive Compulsive Drinking Scale) questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Interaction between subjective alcohol effects and placebo/naltrexone effects</measure>
    <time_frame>28 days</time_frame>
    <description>Exploratively, the interaction between subjective alcohol effects and placebo/naltrexone effects will be investigated using ESA (Erfassung subjektiver Alkoholwirkungen (Determination of subjective alcohol effects)) questionnaire.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Alcohol Addiction</condition>
  <arm_group>
    <arm_group_label>First Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET followed by 7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET - 7 days naltrexone intake (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) - injection of physiological saline solution (0,9%) - PET</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Third Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET - 7 days naltrexone (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) intake - i.v. injection of ethanol solution (6 Vol.-%) - PET</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral tablet daily</description>
    <arm_group_label>First Arm</arm_group_label>
    <arm_group_label>Second Arm</arm_group_label>
    <arm_group_label>Third Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Naltrexone (Nemexin) oral tablet 50 mg daily for 2 days, Naltrexone (Nemexin) oral tablet 100 mg daily for 5 days</description>
    <arm_group_label>Second Arm</arm_group_label>
    <arm_group_label>Third Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age: 21-45 years&#xD;
&#xD;
          -  The subject is able to understand the nature, extent and individual consequences of&#xD;
             the clinical trial&#xD;
&#xD;
          -  Maintained ability to give consent, certified by a psychiatrist (specialist)&#xD;
&#xD;
          -  A personally dated informed consent form signed by the test participant&#xD;
&#xD;
          -  No current and/or historical psychiatric disorder (secured by standardized psychiatric&#xD;
             interview (DIAX: Composite International Diagnostic Interview))&#xD;
&#xD;
          -  Non-smokers (no nicotine addiction within the last 6 months prior to sequential&#xD;
             allocation)&#xD;
&#xD;
          -  OPRM1 Asp40 carrier (functional polymorphism in amino acid residue 40 of μ-opioid&#xD;
             receptor gene (OPRM1)) (in AC for inclusion in first and third treatment arm)&#xD;
&#xD;
          -  Highly effective contraception method with a failure rate of &lt;1%: Hormonal&#xD;
             contraceptive methods (oral: &quot;contraceptive pill&quot;, incl. combined oral contraceptives;&#xD;
             subcutaneous implants; injectable contraceptives); intrauterine pessary, vasectomy of&#xD;
             the partner, tube ligation (&quot;sterilisation&quot;) or sexual abstinence&#xD;
&#xD;
          -  Persons who are legally competent and mentally able to understand and follow the&#xD;
             instructions of the study staff&#xD;
&#xD;
          -  MRI capability&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypersensitivity to the investigational product or a chemically similar substance or&#xD;
             component of the investigational product&#xD;
&#xD;
          -  Participation in other clinical trials during or within 6 months prior to this&#xD;
             clinical trial&#xD;
&#xD;
          -  Medical or psychological circumstances which may jeopardise the proper conduct of the&#xD;
             clinical trial&#xD;
&#xD;
          -  Physical illnesses which could interfere with the planned examinations according to&#xD;
             their type and severity, could have an influence on the parameters to be examined or&#xD;
             could endanger the volunteer during the course of the examination&#xD;
&#xD;
          -  Inability to adhere to the study protocol&#xD;
&#xD;
          -  Limited or completely revoked legal capacity&#xD;
&#xD;
          -  Acute suicidal tendency or external hazard&#xD;
&#xD;
          -  Poor overall condition&#xD;
&#xD;
          -  Participation in a study using ionising radiation in the last five years.&#xD;
&#xD;
          -  Regular medication (e.g. MAO inhibitors)&#xD;
&#xD;
          -  Alcohol abuse, alcohol dependency or addiction illness / abuse of addictive substances&#xD;
             in history&#xD;
&#xD;
          -  Existence of other exclusion criteria for participation in MRI examinations&#xD;
             (non-removable metal parts in the body, left-handedness, pacemakers)&#xD;
&#xD;
          -  Known hypersensitivity to carbidopa or any of the other components&#xD;
&#xD;
          -  Relevant organic diseases: in particular: Narrow angle glaucoma, vascular diseases,&#xD;
             central nervous neurological diseases; body weight of more than 150 kg&#xD;
             (contraindications PET - scan)&#xD;
&#xD;
          -  Clinically significant deviations in clinical chemistry or haematology or clinically&#xD;
             significant abnormalities&#xD;
&#xD;
          -  Melanoma-specific skin lesions or anamnesis of a previous melanoma disease&#xD;
&#xD;
          -  Persons who are accommodated in an establishment by court order or official order&#xD;
&#xD;
          -  Persons who are dependent on or have an employment relationship with the sponsor or&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

